To test the potential that CerS4 may serve as a therapeutic target for overcoming MDR in breast cancer, CerS expression in Adriamycin (AD, also known as doxorubicin)-resistant MCF-7/ADR cells was analyzed. The gene discussed is CERS4; the disease is breast carcinoma.